The national stewardship of biomedical research direction and dollars has experienced a revitalization in the past year with the appointment of Dr. Francis Collins as NIH director, the recent additions of Drs. Eric Green and Harold Varmus as the new directors of the National Human Genome Research Institute (NHGRI) and National Cancer Institute (NCI), respectively, and the open leadership position at the National Institute of Child Health and Human Development (NICHD). It is evident that the transition of leadership in any organization creates anxiety and opportunity. Publicly funded biomedical research is an engine of creativity, providing education and research breakthroughs that change the practice of health care, improve the diagnosis and treatment of disease, and categorically lead to a more complete understanding of the fundamental processes that underlie the way biological systems work. Better health and basic discovery are the two pillars upon which NIH rests.
These ideals are supported by a $31 billion annual budget, which has been stretched to support both NIH campusbased intramural research and extramural research. Despite the nation's fiscal challenges, the need for publicly funded research has never been greater. Certainly, the political realities of funding scientific research may cause some to challenge or doubt its inherent value. Yet, the products of research demonstrate their value in new medicines, new technologies, and new ideas that improve America's physical health as well as its economic health. While much of the focus lies on the tangible goods produced by research (drugs, treatments, lifestyle changes, etc.), it cannot be denied that these discoveries can lead in unintended ways to the next generation of solutions to major health issues. These unpredictable, and often intangible, discoveries are themselves a product of federally funded research and hold a value equal to the more commonly recognized ''real'' discoveries.
The NICHD was organized in 1962 at the request of President Kennedy to address the critical issues surrounding human development and health throughout the entire lifespan. The Institute was recently renamed the Eunice Kennedy Shriver National Institute of Child Health and Human Development in honor of the late President's sister, who devoted her life to advocating research of genetic and developmental diseases. The cornerstone of the Institute is research to improve infant and maternal health, provide reproductive options for men and women, and reduce the impact of the environment and infectious agents on the health of women and children. The scientific research funded by this Institute has had a profound impact on health, leading to some of the most significant advances in child, maternal, and reproductive health in the 20th century. For example, infant mortality rates have dropped more than 70% in the U.S. Additionally, there has been a 90% increase in survival rates for respiratory distress syndrome, and the number of children dying of sudden infant death syndrome (SIDS) has dropped more than 50%. HIV transmission from mother to fetus has been reduced from 25% to 2%. In the reproductive sciences, the Institute has been responsible for the development of fertility management strategies, including new options to preserve fertility for cancer patients and the development of the home pregnancy test. These products are representative of the major areas of work sponsored by the NICHD.
The Institute currently seeks new leadership to reinvigorate the work of individual research scientists, clinical investigators, and the intramural research staff. The new director must provide a vision for the reproductive health of the nation and the healthy development of its children. The NICHD research portfolio is expansive, and will require the director to be equally expansive in their vision. The Institute is positioned to lead the way in integration of social and biological levels of analysis and population and bench science perspectives. The director will be called upon to describe the limits of our present knowledge and how science can assist when the causes of disease are elusive and patients struggle with chronic and debilitating illnesses. This individual must clearly articulate the importance of developmental and reproductive health science research, and the long-term benefits of establishing health early in life, to create a value proposition that is meaningful to both the public and to Congress. The new director must be the main translator of discoveries from the bench and outcomes from population-based studies to clinical opportunities. The ideal leader of NICHD must be able to advocate strongly for research that will ultimately improve the health of men, women, and children by expanding funding opportunities through individual investigator and team-based grants. Finally, the new director must inspire and motivate junior, mid-level, and senior scientists who may be uneasy about the ability to sustain their work and livelihood in the current climate. These are important aspects of the position, but represent just a fraction of the real work required by the NICHD director.
This job comes with several inherent challenges. In five of the past six years, the NICHD has had the lowest funding success rate of research project grants of all Institutes (Fig. 1 , available online at www.biolreprod.org). The new director must clearly articulate the value of population science, reproductive health research, and children's health research and must commit to reversing the trend in NICHD funding. Of course, politics is ever present in the parlance of the NICHD, which considers projects that involve stem cell biology, the egg, sperm and embryo, and interventions in children and pregnant women. But this challenge also presents an incredible opportunity to drive a national discussion about these issues and create a common language that will facilitate continued development of new technologies in the service of the society that will use them. Finally, the tactics and metrics of success are critical but complex. There is a requirement for public funds to flow in a way that makes every dollar convert to new ideas and impact human health as quickly as possible. The new director must be the best steward of these funds and make decisions that accelerate the pace and quality of the work both into publication and into practice.
With the changing leadership at NIH and in the Institute, we now have an unparalleled opportunity to accelerate discovery research and translate knowledge into practice, molecules into drugs, and dollars into better health. The director of NICHD will join a powerful group of leaders who are driving the nation's biomedical research engine. With a clear vision that can be effectively communicated to both Congress and the public, and renewed energy for improving health and health care through individual and team-based research, the NICHD can lead the world in basic and clinical research that impacts the development and reproductive health of the nation.
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